FDA signs off on Gilead's massive new CAR-T manufacturing site in Maryland

Josh Sullivan

Earlier this month, Gilead’s Kite landed an approval for Yescarta in large B-cell lymphoma, making it the first CAR-T available in the second-line lymphoma setting …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA signs off on Gilead's massive new CAR-T manufacturing site in Maryland

Josh Sullivan

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

FDA signs off on Gilead­'s mas­sive new CAR-T man­u­fac­tur­ing site in Mary­land

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

FDA signs off on Gilead's massive new CAR-T manufacturing site in Maryland